Cargando…

Unintended consequences of glucagon-like peptide-1 receptor agonists medications in children and adolescents: A call to action

Detalles Bibliográficos
Autores principales:	Cooper, Dan M., Rothstein, Mark A., Amin, Alpesh, Hirsch, Jan D., Cooper, Emma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495825/ https://www.ncbi.nlm.nih.gov/pubmed/37706005 http://dx.doi.org/10.1017/cts.2023.612

Ejemplares similares

Efficacy of glucagon-like peptide-1 mimetics for neural regeneration
por: Sango, Kazunori, et al.
Publicado: (2015)

Protective potential of glucagon like peptide 2 (GLP-2) against the neurodegeneration
por: Amato, Antonella, et al.
Publicado: (2019)

Upper and/or lower gastrointestinal adverse events with glucagon‐like peptide‐1 receptor agonists: Incidence and consequences
por: Horowitz, Michael, et al.
Publicado: (2017)

Accounting for unintended consequences of resource policy: Connecting research that addresses displacement of environmental impacts
por: Lewison, Rebecca L., et al.
Publicado: (2019)

Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
por: Ard, Jamy, et al.
Publicado: (2021)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?
por: Basalay, Maryna V., et al.
Publicado: (2020)

Unintended Consequences of Conservation Actions: Managing Disease in Complex Ecosystems
por: Chauvenet, Aliénor L. M., et al.
Publicado: (2011)

Glucagon‐like peptide‐1 receptor agonist prescribing patterns in adolescents with type 2 diabetes
por: Bensignor, Megan O., et al.
Publicado: (2022)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Correction: Unintended Consequences of Conservation Actions: Managing Disease in Complex Ecosystems
por: Chauvenet, Aliénor L. M., et al.
Publicado: (2012)

Cardioprotective Actions of a Glucagon‐like Peptide‐1 Receptor Agonist on Hearts Donated After Circulatory Death
por: Kadowaki, Sachiko, et al.
Publicado: (2023)

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists
por: Zhang, Yu-Juan, et al.
Publicado: (2013)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
por: Delgado, A., et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023)

Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement
por: Giorgino, Francesco, et al.
Publicado: (2018)

Unintended consequences of technology improvement
por: McGee, W, et al.
Publicado: (2010)

Call to action: improving primary care for women with COPD
por: Tsiligianni, Ioanna, et al.
Publicado: (2017)

Calling for a united action to defeat COVID-19
por: Overby, Madison, et al.
Publicado: (2020)

Call to Action for Enhanced Equity and Inclusion in Cannabis Research
por: Martin-Willett, Renée, et al.
Publicado: (2021)

Molecular biology for green recovery—A call for action
por: Rodríguez-Martínez, Marta, et al.
Publicado: (2022)

A Call to Action for Gender Equity in Climate Leadership
por: Wray, Britt, et al.
Publicado: (2023)

Call to Action for Advancing Equitable Genomic Newborn Screening
por: Ersig, Anne L., et al.
Publicado: (2023)

The cholera outbreak in Syria: a call for urgent actions
por: Alhaffar, MHD Bahaa Aldin, et al.
Publicado: (2023)

Glucagon peptide-like 1 receptor (GLP-1R) expression per se: a new insight into neurodegenerative disease?
por: Kim, Dong-il, et al.
Publicado: (2015)

HIV and adolescent girls and young women in sub‐Saharan Africa: A call for expedited action to reduce new infections
por: Murewanhema, Grant, et al.
Publicado: (2022)

Tracking Career Outcomes for Postdoctoral Scholars: A Call to Action
por: Silva, Elizabeth A., et al.
Publicado: (2016)

Low availability of code in ecology: A call for urgent action
por: Culina, Antica, et al.
Publicado: (2020)

Medicalization of poverty: a call to action for America’s healthcare workforce
por: Jones, Danielle D
Publicado: (2022)

Obesity in the USMLE Step 1 examination: A call to action
por: Olson, Amber, et al.
Publicado: (2023)

Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study
por: Yan, Yilong, et al.
Publicado: (2023)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung, Tara, et al.
Publicado: (2015)

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
por: Lorenz, Martin, et al.
Publicado: (2017)

Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
por: Madsbad, Sten
Publicado: (2015)

Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes
por: Thieu, Vivian T, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dp6t94bvkevr1etcve0401g4pt